Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9680069 | 0.86 | MEN1 (0.46) | MEN1KMT2AALDH1A1KDM4CCREBBP | |
| SCHEMBL1933912 | 0.84 | MEN1 (0.49) | MEN1KMT2AALDH1A1KDM4CCREBBP | |
| SCHEMBL8014306 | 0.83 | MEN1 (0.58) | MEN1KMT2AALDH1A1KDM4CL3MBTL1 | |
| SCHEMBL21657581 | 0.83 | MEN1 (0.48) | MEN1KMT2AALDH1A1KDM4CCREBBP | |
| SCHEMBL3816272 | 0.83 | KMT2A (0.43) | MEN1KMT2AKDM4CCREBBPTP53 | |
| SCHEMBL1338950 | 0.83 | MEN1 (0.43) | MEN1KMT2AKDM4CCREBBPTP53 | |
| SCHEMBL26187811 | 0.82 | MEN1 (0.44) | MEN1KMT2AALDH1A1KDM4CCREBBP | |
| SCHEMBL9490603 | 0.81 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1ICAM1 | |
| SCHEMBL2150975 | 0.81 | MEN1 (0.52) | MEN1KMT2AALDH1A1KDM4CCREBBP | |
| SCHEMBL9655459 | 0.80 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44768-E1 | Rapamycin hydroxyesters | WYETH LLC (US) | 2014-02-18 | — | — | US | claimed |
| EP-1760083-A1 | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them | Wyeth (US) | 2007-03-07 | — | — | EP | claimed |
| EP-1266899-B1 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | WYETH CORP (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1266899-A2 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | Wyeth (US) | 2002-12-18 | — | — | EP | claimed |
| EP-0763039-A1 | RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995028406-A1 | RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-10-26 | — | — | WO | claimed |
| US-5362718-A | Rapamycin hydroxyesters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | claimed |
| EP-3774786-B1 | METHOD FOR THE PREPARATION OF A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | BAYER AG (DE) | 2024-12-25 | — | — | EP | disclosed |
| CN-112236426-B | Process for preparing 2,4, 5-trisubstituted 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| CN-110637025-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11365179-B2 | Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-21 | — | — | US | disclosed |
| US-11365179-B2 | Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-21 | — | — | US | disclosed |
| US-5362718-A | Rapamycin hydroxyesters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| US-5315012-A | Prevention of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-05-24 | — | — | US | disclosed |
| US-5250561-A | Anticholesterool agents; prevention of hyperlipoproteinemia and atherosclerosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0529854-A2 | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-03-03 | — | — | EP | disclosed |
| US-5134155-A | Anticholesterol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-4378314-A | FOR PENICILLINS AND CEPHALOSPORINS | BRISTOL MYERS COMPANY (US) | 1983-03-29 | — | — | US | disclosed |
| US-4272437-A | PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | MEN1 3042/4885KMT2A 4011/4885ALDH1A1 311/4885 |
| US-11365179-B2 | Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone | TES, CYP51A1, CYP4B1 | MEN1 86/4885KMT2A 3495/4885ALDH1A1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.